CD274 and neoplasm: Before TMB was investigated as a biomarker for ICI efficacy, research focused on programmed-death ligand-1 (PDL-1) expression in the tumor microenvironment (TME); the binding of programmed death cell receptor-1 (PD-1) to PD-L1 limits activation of T cells and subsequently decreases the immune response to cancer cells [6].